255 related articles for article (PubMed ID: 22393708)
41. Lentiviral vectors and gene therapy.
Klimatcheva E; Rosenblatt JD; Planelles V
Front Biosci; 1999 Jun; 4():D481-96. PubMed ID: 10352135
[TBL] [Abstract][Full Text] [Related]
42. Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors.
Di Nunzio F; Maruggi G; Ferrari S; Di Iorio E; Poletti V; Garcia M; Del Rio M; De Luca M; Larcher F; Pellegrini G; Mavilio F
Mol Ther; 2008 Dec; 16(12):1977-85. PubMed ID: 18813277
[TBL] [Abstract][Full Text] [Related]
43. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.
Dahl M; Doyle A; Olsson K; Månsson JE; Marques ARA; Mirzaian M; Aerts JM; Ehinger M; Rothe M; Modlich U; Schambach A; Karlsson S
Mol Ther; 2015 May; 23(5):835-844. PubMed ID: 25655314
[TBL] [Abstract][Full Text] [Related]
44. Clinical use of lentiviral vectors.
Milone MC; O'Doherty U
Leukemia; 2018 Jul; 32(7):1529-1541. PubMed ID: 29654266
[TBL] [Abstract][Full Text] [Related]
45. Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases.
Poletti V; Mavilio F
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452394
[TBL] [Abstract][Full Text] [Related]
46. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research.
Dropulić B
Hum Gene Ther; 2011 Jun; 22(6):649-57. PubMed ID: 21486177
[TBL] [Abstract][Full Text] [Related]
47. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.
Modlich U; Navarro S; Zychlinski D; Maetzig T; Knoess S; Brugman MH; Schambach A; Charrier S; Galy A; Thrasher AJ; Bueren J; Baum C
Mol Ther; 2009 Nov; 17(11):1919-28. PubMed ID: 19672245
[TBL] [Abstract][Full Text] [Related]
48. Identification of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus.
Yamada K; Tsukahara T; Yoshino K; Kojima K; Agawa H; Yamashita Y; Amano Y; Hatta M; Matsuzaki Y; Kurotori N; Wakui K; Fukushima Y; Osada R; Shiozawa T; Sakashita K; Koike K; Kumaki S; Tanaka N; Takeshita T
Retrovirology; 2009 Sep; 6():79. PubMed ID: 19725963
[TBL] [Abstract][Full Text] [Related]
49. Biosafety features of lentiviral vectors.
Schambach A; Zychlinski D; Ehrnstroem B; Baum C
Hum Gene Ther; 2013 Feb; 24(2):132-42. PubMed ID: 23311447
[TBL] [Abstract][Full Text] [Related]
50. Lentiviral vector gene therapy: effective and safe?
Persons DA
Mol Ther; 2010 May; 18(5):861-2. PubMed ID: 20436489
[No Abstract] [Full Text] [Related]
51. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
Beard BC; Keyser KA; Trobridge GD; Peterson LJ; Miller DG; Jacobs M; Kaul R; Kiem HP
Hum Gene Ther; 2007 May; 18(5):423-34. PubMed ID: 17518616
[TBL] [Abstract][Full Text] [Related]
52. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
53. Effective gene therapy with nonintegrating lentiviral vectors.
Yáñez-Muñoz RJ; Balaggan KS; MacNeil A; Howe SJ; Schmidt M; Smith AJ; Buch P; MacLaren RE; Anderson PN; Barker SE; Duran Y; Bartholomae C; von Kalle C; Heckenlively JR; Kinnon C; Ali RR; Thrasher AJ
Nat Med; 2006 Mar; 12(3):348-53. PubMed ID: 16491086
[TBL] [Abstract][Full Text] [Related]
54. Taking the good out of the bad: lentiviral-based gene therapy of the hemoglobinopathies.
Stathopulos PB
Biotechnol Adv; 2003 Sep; 21(6):513-26. PubMed ID: 14499152
[TBL] [Abstract][Full Text] [Related]
55. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
56. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
57. Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector.
Zhou S; Ma Z; Lu T; Janke L; Gray JT; Sorrentino BP
PLoS One; 2013; 8(4):e62333. PubMed ID: 23626802
[TBL] [Abstract][Full Text] [Related]
58. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
[TBL] [Abstract][Full Text] [Related]
59. [New hope of gene therapy results from improvements of lentiviral vectors-review].
Fang F; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1336-9. PubMed ID: 24156461
[TBL] [Abstract][Full Text] [Related]
60. A novel inducible lentiviral system for multi-gene expression with human HSP70 promoter and tetracycline-induced promoter.
Li S; Ma L; Ou M; Feng J; Liao Y; Wang G; Tang L
Appl Microbiol Biotechnol; 2017 May; 101(9):3689-3702. PubMed ID: 28160047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
